Results
MCI
INTERACTION, IDC, MRS, INVASIVE DUCTAL CARCINOMA
In this study, we performed two interim analyses with 30% and 50% of the anticipated sample size. Both analyses confirmed the non-inferiority of drugs B and C compared to A. So, we achieved a final analysis on 133 patients of group A (n = 43), group B (n = 47), and group C (n = 43). A few participants were excluded as follows: one subject in group A (due to change of the oncologist), four in group B (due to loss to follow-up in MCI clinic), and three in group C (due to loss to follow-up and discontinuation of the drugs) (Fig. Demographic and clinical characteristics of the participants in three arms are shown in Table 
Demographic and clinical characteristics of participants and comparison among the groups*Chi-square test** One-Way ANOVA test***Kruskal-Wallis testMRS: Menopause rating scale. Her2: Human epidermal growth factor receptor 2. IDC: Invasive ductal carcinoma. BMI: Body mass index. FSH: Follicle stimulating hormoneTable 
Changes in FSH and estradiol during the three-month intervals in groups A, B and CPP
One-year changes in serum FSH Changes in MRS and its subscales scores are summarized in Table 
One-year mean changes of MRS score and its subscale within and between groupsPP
One-year changes in the mean score of MRS in the three groups of studyGEE was used to adjust the interaction effect of time and group variables in order to compare the effectiveness and side effects of the drugs among the three groups within the study period of one year (Table Injection of Microrelin 3.75 and Microrelin 11.25 reduced the mean FSH level more than Diphereline 11.25 by up to 0.88 and 1.25 units per three months, respectively.According to the findings (Table 
Interaction of time and group effect with the total MRS score, serum estradiol and FSH levels*Adjusted for time and group